Brief Review on Liposomes as Targeted Therapeutics in Breast Cancer

One of the biggest causes of cancer-related fatalities globally is still breast cancer.Conventional chemotherapy is often limited by systemic toxicity, drug resistance, and inadequate targeting. Liposomes, nanoscale vesicles, have emerged as promising targeted drug delivery systems for breast cancer therapy. This review highlights the potential of liposomes as targeted therapeutics in breast cancer, focusing on their ability to enhance drug efficacy, reduce toxicity, and improve patient outcomes. We discuss various liposome formulations, targeting mechanisms, and clinical trials evaluating liposomal doxorubicin, paclitaxel, and other chemotherapeutics. The review also addresses challenges, future directions, and potential combination therapies. Our analysis demonstrates that liposomes hold significant promise for improving breast cancer treatment, offering personalized medicine approaches and enhanced therapeutic outcomes.